Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Reata Pharmaceuticals, Inc. RETA
$84.71
-$3.18 (-3.75%)
На 18:00, 12 мая 2023
-26.02%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3757954216.00000000
-
week52high
106.69
-
week52low
18.47
-
Revenue
2216000
-
P/E TTM
-12
-
Beta
1.52906500
-
EPS
-8.82000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Baird | Neutral | Neutral | 09 авг 2022 г. |
| Citigroup | Buy | Buy | 27 мая 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Goldman Sachs | Buy | Neutral | 24 мар 2022 г. |
| Goldman Sachs | Neutral | Neutral | 01 мар 2022 г. |
| Guggenheim | Buy | 19 окт 2022 г. | |
| Goldman Sachs | Buy | Buy | 09 ноя 2022 г. |
| Citigroup | Buy | Buy | 09 ноя 2022 г. |
| Barclays | Overweight | Overweight | 09 ноя 2022 г. |
| Goldman Sachs | Buy | Buy | 28 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Huff James Warren | A | 190950 | 190950 | 03 янв 2023 г. |
| Huff James Warren | A | 47025 | 47025 | 03 янв 2023 г. |
| Soni Manmeet Singh | A | 95475 | 95475 | 03 янв 2023 г. |
| Soni Manmeet Singh | A | 92513 | 23513 | 03 янв 2023 г. |
| WORTLEY MICHAEL D | A | 63650 | 63650 | 03 янв 2023 г. |
| WORTLEY MICHAEL D | A | 50675 | 15675 | 03 янв 2023 г. |
| Meyer Colin John | A | 95475 | 95475 | 03 янв 2023 г. |
| Meyer Colin John | A | 75513 | 23513 | 03 янв 2023 г. |
| Khan Samina | A | 47738 | 47738 | 03 янв 2023 г. |
| Khan Samina | A | 46905 | 11756 | 03 янв 2023 г. |
Новостная лента
Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates
Zacks Investment Research
11 мая 2023 г. в 11:25
Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.
Reata Pharmaceuticals, Inc. (RETA) Q1 2023 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 00:04
Reata Pharmaceuticals, Inc. (NASDAQ:RETA ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Warren Huff - Chairman and Chief Executive Officer Dawn Bir - Executive Vice President and Chief Commercial Officer Andrea Loewen - Senior Vice President of Global Regulatory Affairs Seemi Khan - Senior Vice President and Chief Medical Officer Colin Meyer - Executive Vice President and Chief Innovation Officer Manmeet Soni - President, Chief Operating Officer and Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Madhu Kumar - Goldman Sachs Yatin Suneja - Guggenheim Securities Charles Duncan - Cantor Fitzgerald Carter Gould - Barclays Annabel Samimy - Stifel Maury Raycroft - Jefferies Matthew Kaplan - Ladenburg Thalmann Operator Thank you for standing by, and welcome to the Reata Pharmaceuticals First Quarter Financial Results Update on Operational Progress and Development Programs Conference Call. An audio recording of today's webcast will be available shortly after the call in the Investor section of Reata's website at reatapharma.com.
Reata Pharma Tumbles After Scrapping Its Kidney Drug As Earnings Come In Mixed
Investors Business Daily
10 мая 2023 г. в 09:21
Reata Pharmaceuticals is scrapping development of a kidney disease drug and put up mixed earnings Wednesday. RETA stock tumbled.
Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023
Business Wire
02 мая 2023 г. в 17:45
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical, company focused on developing and commercializing novel therapies for patients with severe diseases, today announced that it will report financial results for the first quarter ended March 31, 2023, and provide an update on the Company's business operations and clinical development programs on May 10, 2023, before the U.S. financial markets open.
Reata Pharmaceuticals: Still A Buy After Skyclarys Approval Jump
Seeking Alpha
29 апр 2023 г. в 05:21
Reata graduated to owning a commercial pharmaceutical product on February 28. Projecting timing for Skyclarys or any new therapy's revenue ramp is difficult.